tiprankstipranks
Stoke Therapeutics Inc (DE:0GT)
FRANKFURT:0GT
Germany Market
0GT
Stoke Therapeutics
RESEARCH TOOLSreports

Stoke Therapeutics (0GT) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0GT Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Stoke
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0GT Stock 12 Month Forecast

Average Price Target

€38.97
▲(38.24% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is €38.97 with a high forecast of €51.50 and a low forecast of €30.04. The average price target represents a 38.24% change from the last price of €28.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","31":"€31","52":"€52","20.5":"€20.5","41.5":"€41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51.5016156,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€51.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.96955580400001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€38.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.0426091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€30.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.5,31,41.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,27.860124276923077,29.830248553846154,31.80037283076923,33.77049710769231,35.74062138461539,37.71074566153846,39.68086993846154,41.650994215384614,43.621118492307694,45.591242769230774,47.56136704615385,49.53149132307692,{"y":51.5016156,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,26.89611967723077,27.90223935446154,28.90835903169231,29.91447870892308,30.92059838615385,31.92671806338462,32.93283774061539,33.93895741784616,34.945077095076925,35.951196772307696,36.95731644953847,37.96343612676924,{"y":38.96955580400001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,26.20943146923077,26.52886293846154,26.848294407692308,27.16772587692308,27.487157346153847,27.806588815384615,28.126020284615386,28.445451753846154,28.76488322307692,29.084314692307693,29.40374616153846,29.723177630769232,{"y":30.0426091,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.25,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.89,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€51.50Average Price Target€38.97Lowest Price Target€30.04
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on DE:0GT
Jessica Fye
J.P. Morgan
J.P. Morgan
€34.33
Buy
21.80%
Upside
Initiated
08/21/26
Stoke Therapeutics reinstated with an Overweight at JPMorganStoke Therapeutics reinstated with an Overweight at JPMorgan
Canaccord Genuity Analyst forecast on DE:0GT
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€49.78
Buy
76.60%
Upside
Reiterated
08/12/26
Stoke Therapeutics (STOK) Gets a Buy from Canaccord Genuity
TD Cowen Analyst forecast on DE:0GT
Yaron Werber
TD Cowen
TD Cowen
€51.5
Buy
82.69%
Upside
Reiterated
08/04/26
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
Needham Analyst forecast on DE:0GT
Joseph Stringer
Needham
Needham
€34.33
Buy
21.80%
Upside
Reiterated
08/04/26
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
H.C. Wainwright Analyst forecast on DE:0GT
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€42.92
Buy
52.25%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Wolfe Research Analyst forecast on DE:0GT
Rudy Li
Wolfe Research
Wolfe Research
€34.33
Buy
21.80%
Upside
Reiterated
08/03/26
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
BTIG Analyst forecast on DE:0GT
Thomas Shrader
BTIG
BTIG
€33.48
Buy
18.75%
Upside
Reiterated
08/03/26
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
Chardan Capital Analyst forecast on DE:0GT
Keay Nakae
Chardan Capital
Chardan Capital
€30.04
Buy
6.57%
Upside
Reiterated
08/03/26
Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
Goldman Sachs Analyst forecast on DE:0GT
Kevin Strang
Goldman Sachs
Goldman Sachs
€37.77
Buy
33.98%
Upside
Reiterated
08/03/26
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
Jefferies Analyst forecast on DE:0GT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€33.48→€41.2
Buy
46.16%
Upside
Reiterated
07/06/26
Stoke Therapeutics (STOK) Receives a Buy from Jefferies
Leerink Partners Analyst forecast on DE:0GT
Marc Goodman
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Stoke Therapeutics (STOK) Gets a Buy from Leerink Partners
Wedbush Analyst forecast on DE:0GT
Laura Chico
Wedbush
Wedbush
€32.62
Buy
15.71%
Upside
Reiterated
05/08/26
Stoke Therapeutics (STOK) Gets a Buy from Wedbush
Guggenheim Analyst forecast on DE:0GT
Yatin Suneja
Guggenheim
Guggenheim
€51.5
Buy
82.69%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Guardant Health (NASDAQ: GH) and Stoke Therapeutics (NASDAQ: STOK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on DE:0GT
Jessica Fye
J.P. Morgan
J.P. Morgan
€34.33
Buy
21.80%
Upside
Initiated
08/21/26
Stoke Therapeutics reinstated with an Overweight at JPMorganStoke Therapeutics reinstated with an Overweight at JPMorgan
Canaccord Genuity Analyst forecast on DE:0GT
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€49.78
Buy
76.60%
Upside
Reiterated
08/12/26
Stoke Therapeutics (STOK) Gets a Buy from Canaccord Genuity
TD Cowen Analyst forecast on DE:0GT
Yaron Werber
TD Cowen
TD Cowen
€51.5
Buy
82.69%
Upside
Reiterated
08/04/26
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
Needham Analyst forecast on DE:0GT
Joseph Stringer
Needham
Needham
€34.33
Buy
21.80%
Upside
Reiterated
08/04/26
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
H.C. Wainwright Analyst forecast on DE:0GT
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€42.92
Buy
52.25%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Wolfe Research Analyst forecast on DE:0GT
Rudy Li
Wolfe Research
Wolfe Research
€34.33
Buy
21.80%
Upside
Reiterated
08/03/26
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
BTIG Analyst forecast on DE:0GT
Thomas Shrader
BTIG
BTIG
€33.48
Buy
18.75%
Upside
Reiterated
08/03/26
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
Chardan Capital Analyst forecast on DE:0GT
Keay Nakae
Chardan Capital
Chardan Capital
€30.04
Buy
6.57%
Upside
Reiterated
08/03/26
Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
Goldman Sachs Analyst forecast on DE:0GT
Kevin Strang
Goldman Sachs
Goldman Sachs
€37.77
Buy
33.98%
Upside
Reiterated
08/03/26
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
Jefferies Analyst forecast on DE:0GT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€33.48→€41.2
Buy
46.16%
Upside
Reiterated
07/06/26
Stoke Therapeutics (STOK) Receives a Buy from Jefferies
Leerink Partners Analyst forecast on DE:0GT
Marc Goodman
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Stoke Therapeutics (STOK) Gets a Buy from Leerink Partners
Wedbush Analyst forecast on DE:0GT
Laura Chico
Wedbush
Wedbush
€32.62
Buy
15.71%
Upside
Reiterated
05/08/26
Stoke Therapeutics (STOK) Gets a Buy from Wedbush
Guggenheim Analyst forecast on DE:0GT
Yatin Suneja
Guggenheim
Guggenheim
€51.5
Buy
82.69%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Guardant Health (NASDAQ: GH) and Stoke Therapeutics (NASDAQ: STOK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stoke Therapeutics

3 Months
Yaron WerberTD Cowen
Success Rate
10/16 ratings generated profit
63%
Average Return
+9.72%
Copying Yaron Werber's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +9.72% per trade.
1 Year
Sumant KulkarniCanaccord Genuity
Success Rate
12/16 ratings generated profit
75%
Average Return
+89.83%
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +89.83% per trade.
2 Years
Sumant KulkarniCanaccord Genuity
Success Rate
14/16 ratings generated profit
88%
Average Return
+150.48%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +150.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0GT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
5
3
3
4
Buy
10
11
7
9
11
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
16
10
12
15
In the current month, 0GT has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0GT average Analyst price target in the past 3 months is 38.97.
Each month's total comprises the sum of three months' worth of ratings.

0GT Financial Forecast

0GT Earnings Forecast

Next quarter’s earnings estimate for 0GT is -€0.78 with a range of -€0.90 to -€0.60. The previous quarter’s EPS was -€0.80. 0GT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0GT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0GT is -€0.78 with a range of -€0.90 to -€0.60. The previous quarter’s EPS was -€0.80. 0GT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0GT has Performed in-line its overall industry.

0GT Sales Forecast

Next quarter’s sales forecast for 0GT is €7.02M with a range of €1.80M to €14.97M. The previous quarter’s sales results were €7.98M. 0GT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0GT has Performed in-line its overall industry.
Next quarter’s sales forecast for 0GT is €7.02M with a range of €1.80M to €14.97M. The previous quarter’s sales results were €7.98M. 0GT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0GT has Performed in-line its overall industry.

0GT Stock Forecast FAQ

What is DE:0GT’s average 12-month price target, according to analysts?
Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 38.97.
    What is DE:0GT’s upside potential, based on the analysts’ average price target?
    Stoke Therapeutics Inc has 38.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Stoke Therapeutics Inc a Buy, Sell or Hold?
          Stoke Therapeutics Inc has a consensus rating of Strong Buy, which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Stoke Therapeutics Inc’s share price target?
            The average share price target for Stoke Therapeutics Inc is 38.97. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €51.50 ,and the lowest forecast is €30.04. The average share price target represents 38.24% Increase from the current price of €28.19.
              What do analysts say about Stoke Therapeutics Inc?
              Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Stoke Therapeutics Inc?
                To buy shares of DE:0GT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.